USFDA Gives Final Approval to Aurobindo Pharma for Manufacturing Sevelamer Carbonate Oral suspension
DSIJ Intelligence / 15 Jun 2017
Aurobindo Pharma Limited is engaged in producing oral and injectable generic formulations and active pharmaceutical ingredients (APIs).
The US Food & Drug Administration (U.S. FDA) gave its final approval to Aurobindo Pharma to manufacture Sevelamer Carbonate Oral suspension, 0.8 gm and 2.4 gm, the company informed the bourses on Thursday.
Aurobindo Pharma Limited is engaged in producing oral and injectable generic formulations and active pharmaceutical ingredients (APIs).
Sevelamer Carbonate oral suspension is prescribed for the control of serum phosphorus in patients with chronic kidney disease.
Meanwhile, at Rs 638.55 per share at 1128 hours IST on BSE, the stock was trading higher by 6.1%. It hit a high of Rs 640.80 and a low of Rs 600.75 so far during the day. The stock has under performed BSE Sensex and BSE Healthcare index over a period of one year.